Refractory Multiple Myeloma

Oncology·MeSH: Multiple Myeloma

Prevalence

17.0 / 100K

Incidence

7.0 / 100K/yr

62 drugs in development·31 companies·16 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
bortezomib	Teva Pharmaceutical Industries Limited (TEVA)

Phase 3(21)

Drug	Company
anitocabtagene autoleucel	GILEAD SCIENCES, INC. (GILD)
bb2121	CELGENE CORP /DE/ (CELG)
bortezomib	AbbVie Inc. (ABBV)
carfilzomib	Sanofi (SNY)
Carfilzomib	BRISTOL MYERS SQUIBB CO (BMY)
daratumumab	REGENERON PHARMACEUTICALS, INC. (REGN)
daratumumab	ASTRAZENECA PLC (AZN)
daratumumab	Juno Therapeutics, Inc. (JUNO)
Daratumumab	BRISTOL MYERS SQUIBB CO (BMY)
descartes-15	Cartesian Therapeutics, Inc. (RNAC)
elotuzumab	REGENERON PHARMACEUTICALS, INC. (REGN)
Manufactured Anti-BCMA CAR-T cells	Filana Therapeutics Inc. (FLNA)
Mezigdomide	BRISTOL MYERS SQUIBB CO (BMY)
montelukast	Sanofi (SNY)
Montelukast	Sanofi (SNY)
Pomalidomide	BeOne Medicines Ltd. (ONC)
Pomalidomide	Merus N.V. (MRUS)
Pomalidomide	BRISTOL MYERS SQUIBB CO (BMY)
sonrotoclax	BeOne Medicines Ltd. (ONC)
teclistamab	GH Research PLC (GHRS)
Teclistamab	Merus N.V. (MRUS)

Phase 2(9)

Drug	Company
allo-715	Allogene Therapeutics, Inc. (ALLO)
Bortezomib	FATE THERAPEUTICS INC (FATE)
EOS-448	iTeos Therapeutics, Inc. (ITOS)
iberdomide	CELGENE CORP /DE/ (CELG)
incb001158	Incyte Corp. (INCY)
nexi-002	NexImmune, Inc. (NEXI)
Part 1	FATE THERAPEUTICS INC (FATE)
Part 2	FATE THERAPEUTICS INC (FATE)
Selinexor	FATE THERAPEUTICS INC (FATE)

Phase 1(16)

Drug	Company
ABT-199	AbbVie Inc. (ABBV)
ACLX-001	Arcellx, Inc. (ACLX)
Carfilzomib	Merus N.V. (MRUS)
CB-011	Caribou Biosciences, Inc. (CRBU)
CLN-619	Cullinan Therapeutics, Inc. (CGEM)
diphenhydramine	Sanofi (SNY)
Efbalropendekin alfa (XmAb306 / RG6323)	Xencor Inc (XNCR)
jnj-79635322	GH Research PLC (GHRS)
jnj-87562761	GH Research PLC (GHRS)
mk-4002	Merck & Co., Inc. (MRK)
nirogacestat	Allogene Therapeutics, Inc. (ALLO)
nxc-201	Immix Biopharma, Inc. (IMMX)
sar445514	Sanofi (SNYNF)
sar445514	Sanofi (SNY)
sti-1492	Sorrento Therapeutics, Inc. (SRNE)
tak-573	Teva Pharmaceutical Industries Limited (TEVA)

Unknown(1)

Drug	Company
LCAR- F33S cells intravenous infusion	Legend Biotech Corp (LEGN)

Phase 1/Phase 2(11)

Drug	Company
Carfilzomib	BeOne Medicines Ltd. (ONC)
daratumumab	GENMAB A/S (GNMSF)
daratumumab	BeOne Medicines Ltd. (ONC)
daratumumab	Genmab A/S (GMAB)
Daratumumab	BeOne Medicines Ltd. (ONC)
daratumumab sc	Incyte Corp. (INCY)
gen3014	Genmab A/S (GMAB)
gen3014	GENMAB A/S (GNMSF)
linvoseltamab	REGENERON PHARMACEUTICALS, INC. (REGN)
regn17372+linvoseltamab	REGENERON PHARMACEUTICALS, INC. (REGN)
regn7945+linvoseltamab	REGENERON PHARMACEUTICALS, INC. (REGN)

Phase 4(3)

Drug	Company
BMS-986393	BRISTOL MYERS SQUIBB CO (BMY)
mRNA-2808	Moderna, Inc. (MRNA)
tocilizumab	REGENERON PHARMACEUTICALS, INC. (REGN)

BioSniper tracks 62 drugs in development for Refractory Multiple Myeloma across 31 companies.

There are 16 clinical trials targeting Refractory Multiple Myeloma tracked by BioSniper.

The estimated prevalence of Refractory Multiple Myeloma is approximately 17.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.